The Trump administration is preparing a pilot program that could allow some Americans on Medicare and Medicaid to access popular and costly weight-loss medications.
The plan, still in development, would permit state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs such as Novo Nordisk A/S’ (NYSE:NVO) Ozempic and Wegovy, and Eli Lilly And Co’s (NYSE:LLY) Mounjaro and Zepbound for weight management, according to internal documents reviewed by The Washington Post.
